Biopure's Stock Symbol Reverts to BPUR
June 27 2005 - 7:04PM
PR Newswire (US)
Biopure's Stock Symbol Reverts to BPUR CAMBRIDGE, Mass., June 27
/PRNewswire-FirstCall/ -- Biopure Corporation (NASDAQ:BPUR)
announced today that the trading symbol for its Class A common
stock will revert from BPURD to BPUR at the open of the market on
Tuesday, June 28, 2005. Biopure Corporation Biopure Corporation
develops and manufactures intravenously administered
pharmaceuticals, called oxygen therapeutics, that deliver oxygen to
the body's tissues. The company is developing Hemopure(R)
[hemoglobin glutamer - 250 (bovine)], or HBOC-201, for a potential
indication in cardiovascular ischemia and, in collaboration with
the U.S. Naval Medical Research Center, for an out- of-hospital
trauma indication. The product is approved in South Africa for
treating surgery patients who are acutely anemic and for
eliminating, delaying or reducing allogeneic red blood cell
transfusions in these patients. Hemopure has not been approved for
sale in any other jurisdictions, including the United States or the
European Union. Biopure's veterinary product Oxyglobin(R)
[hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen
therapeutic approved by the U.S. Food and Drug Administration and
the European Commission, is indicated for the treatment of anemia
in dogs. Contact: Douglas Sayles Biopure Corporation (617) 234-6826
DATASOURCE: Biopure Corporation CONTACT: Douglas Sayles of Biopure
Corporation, +1-617-234-6826, Web site: http://www.biopure.com/
Company News On-Call: http://www.prnewswire.com/comp/131224.html
Copyright